Novel antibody conjugates reactive with human carcinomas

  • US 20020192223A1
  • Filed: 02/12/2001
  • Published: 12/19/2002
  • Est. Priority Date: 06/30/1989
  • Status: Abandoned Application
First Claim
Patent Images

1. A monoclonal antibody BR96 produced by hybridoma ATCC HB 10036, or fragments thereof, and functional equivalents thereof having an antigen-binding region that competitively inhibits the immunospecific binding of monoclonal antibody BR96, having specific immunological reactivity with human carcinoma cells, said antibody characterized by being capable of internalizing within the carcinoma cells with which it reacts, mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity, and/or killing of said human carcinoma cells in the absence of host effector cells or complement.

View all claims

    Thank you for your feedback